| Pathogen |
WHO(2017)
|
CDC(2019)
|
AMED Public and Private Partnerships for Infectious Diseases R&D (APiD)
|
|---|---|---|---|
| MDR Acinetobacter | Critical | Urgent (Carbapenem-R) |
Priority1 |
| MDR Pseudomonas aeruginosa | Critical | Serious(MDR) | Priority1 |
| Carbapenem-R Enterobacterales | Critical | Urgent (Carbapenem-R) |
Priority1 |
| Ceph-R (ESBL+) Enterobacterales | Critical | Serious Ceph-R (ESBL+) |
Priority1 |
| Drug-R Neisseria gonorrhoeae | High | Urgent(drug-R) | Priority1 |
| MDR/XDR Mycobacterium tuberculosis | － | Serious(drug-R) | Priority1 |
| Nontuberculous Mycobacterium (NTM) | － | － | Priority1 |
| Clostridioides difficile | － | Urgent(drug-R) | Priority2 |
| Vancomycin-R Enterococci (VRE) | High | Serious(drug-R) | Priority2 |
| Methicillin-R Staphylococcus aureus (MRSA) | High | Serious(MRSA) | Priority2 |
| Vancomycin-R Staphylococcus aureus | High | － | Priority2 |
| Penicillin non-susceptible Streptococcus pneumoniae (PNSP) | Medium | Serious(drug-R) | Priority2 |
| Drug-R Mycoplasma genitalium | － | Watch list | Priority2 |
| Candida auris | － | Urgent | Priority1 |
| Drug-R Candida | － | Serious(drug-R) | Priority2 |
| Azole-R Aspergillus fumigatus | － | Watch list | Priority2 |
| Drug-R Helicobacter pyroli | High | － | Priority3 |
| Multi-drug resistant Bacteroides fragilis | － | － | Priority3 |
| Drug-R Campylobacter | High | Serious(drug-R) | Priority3 |
| Drug-R Salmonella | High | Serious(drug-R) | Priority3 |
| Fluorloquinolone-resistant Shigella | Medium | Serious | Priority3 |
| βｰlactamase-nonproducing ampicillin resistant Haemophilus influenzae (BLNAR) | Medium (ampicillin-R) |
－ | Priority3 |
| Erythromycin-R group A Streptococcus | － | Concerning (erythromycin-R) |
Priority3 |
| Clindamycin-R group B Streptococcus | － | Concerning (clindamycin-R) |
Priority3 |
| Priority 1 | Bacterial or fungal infection which is difficult to be treated by existing antibiotics nationally and internationally1) and which is expected to develop new antibiotics urgently. 1) Public domains in MHLW, NIID, MOFA, WHO and CDC |
| Priority 2 | Bacterial or fungal infection which is clinically treatable by combinations of existing antibiotics nationally and internationally but which is expected to develop new antibiotics near future. |
| Priority 3 | Bacterial or fungal infection other than the above which requires continuous surveillance and basic research for R&D in order to prepare for medical need of new drug in future. The pathogens not listed this table are categorized “Priority 3” at this moment. |
[Special notes]
Approaches from new view points consider to be supported regardless the listed pathogens recognizing that innovative breakthrough is always required in R&D on AMR.
Regarding Priority, the relationship between the Japanese version, WHO version and CDC version is as follows.
| WHO | Critical | High | Medium | |
| CDC | Urgent | Serious | Concerning | Watch |
| AMED ID PPP | Priority 1 | Priority 2 | Priority 3 | |
| － | No discription |
